La Jolla completes patient dosing in Phase I portion of GCS-100 clinical trial

La Jolla Pharmaceutical has treated the last patient in the Phase I (Part A) portion of its Phase I/II clinical trial of GCS-100 to treat chronic kidney disease (CKD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news